Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium.

  title={Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium.},
  author={Saeed Y Aghdam and Steven W. Barger},
  journal={Current Alzheimer research},
  volume={4 1},
For over fifty years lithium has been a fundamental component of therapy for patients with bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal loss and other neurodegeneration processes. For instance, lithium reduces the severity of some behavioral complications of Alzheimer's disease (AD). And there are growing indications that lithium may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including… 

Tables from this paper

[The role of lithium in neurodegenerative diseases: new registries for old actors].

Lithium, and in a more extensive way, GSK-3 inhibitors, are proposed as a new drug generation with potential action on the progression of different neurodegenerative diseases, especially those related with abnormal aggregation of the protein tau.

A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts

The aim of this review is to briefly summarize the potential benefits of lithium salts on neuroprotection and neuroregeneration, emphasizing preclinical and clinical evidence suggesting new therapeutic potentials of this drug beyond its mood stabilizing properties.

Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models

Generic mechanisms by which lithium preserves neuronal function and improves memory in animal models of dementia are focused on, which have advantages as a multi-functional therapy to combat the complex molecular pathology of dementia.

Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders.

This study compared specific inhibitors of GSK-3 and PDE7 with dual inhibitors of both enzymes with regard to anti-inflammatory effects in primary cultures of glial cells treated with lipopolysaccharide and indicated that the indirect inhibition of G SK-3 by PDE8 inhibitors is an important mechanism that should be considered in the future development of pharmacological treatments.

Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.

It is shown that glycogen synthase kinase 3beta (GSK-3beta) is required for radiation-induced hippocampal neuronal apoptosis and subsequent neurocognitive decline and suggested that GSK-3 beta inhibitors may have a therapeutic role in protecting both pediatric and adult cancer patients and may help to improve quality of life in cancer survivors.

Lítio e expressão gênica: implicações para a doença de Alzheimer.

A significant and dose-dependent reduction in the mRNA levels of Gsk3b, which was specific to hippocampal cells is found, suggesting new regulatory effects of lithium over GSK3β and suggest new potential lithium targets, contributing to the better understanding of its mechanisms of action and reinforcing its potential for the inhibition of key AD pathological pathways.

GSK-3 Inhibitors: From the Brain to the Retina and Back Again.

The potential of GSK-3 inhibitors in the treatment of retinal degeneration is discussed, which allows for easier evaluation of the efficacy of candidate therapies in clinical trials.

Overexpression of glycogen synthase kinase 3β sensitizes neuronal cells to ethanol toxicity

It is demonstrated that glycogen synthase kinase 3β (GSK3β), a multifunctional serine/threonine kinase, was involved in ethanol neurotoxicity.

Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs

Significant amounts of evidence have been accumulated showing preclinical efficacy for these new drugs, in very different models of several distinct pathologies, offering promising examples for new therapies for diabetes, cancer, inflammation, Alzheimer's disease and other neurological Pathologies, and mood disorders.

Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons




Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3*

Using cultured human NT2N neurons, it is demonstrated that lithium reduces the phosphorylation of t Tau, enhances the binding of tau to microtubules, and promotes microtubule assembly through direct and reversible inhibition of glycogen synthase kinase-3.

Lithium Blocks the c-Jun Stress Response and Protects Neurons via Its Action on Glycogen Synthase Kinase 3

It is shown that lithium blocks the canonical c-Jun apoptotic pathway in cerebellar granule neurons deprived of trophic support, and suggests that a GSK-3-like kinase acts in tandem with c-jun N-terminal kinase to coordinate the full execution of the c- Jun stress response and neuronal death in response to Trophic deprivation.

Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.

It is reported that both lithium as well as valproic acid (VPA) inhibit beta-amyloid peptide (Abeta) production in HEK293 cells stably transfected with Swedish amyloid precursor protein (APP)(751) and in the brains of the PDAPP (APP(V717F)) Alzheimer's disease transgenic mouse model at clinically relevant plasma concentrations.

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

  • W. NobleE. Planel K. Duff
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2005
Results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically and that lithium exerts its effect through GSK-3 inhibition.

Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation*

It is hypothesized that lithium treatment may partially rescue death in Huntington's disease cell models, and LiCl is an excellent candidate for further in vivo therapeutic trials.

Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain

It is found that GSK-3 is prominently present in neuronal cell bodies and their processes and co-localizes with neurofibrillary changes in AD brain and is significantly increased in the postsynaptosomal supernatant from AD brains as compared to the controls.

A molecular mechanism for the effect of lithium on development.

  • P. S. KleinD. Melton
  • Biology, Psychology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1996
It is shown that complete inhibition of IMPase has no effect on the morphogenesis of Xenopus embryos and a different hypothesis to explain the broad action of lithium is presented, which suggests that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus.